证券代码：600513 证券简称：联环药业 公告编号：2025—059 江苏联环药业股份有限公司 关于公司《2025 年半年度报告》披露日期变更的公告 1 江苏联环药业股份有限公司（以下简称"公司"）《2025 年半年度报告》 原定于 2025 年 8 月 28 日披露。因公司董事会时间调整，经向上海证券交易所申 请，公司《2025 年半年度报告》披露日期变更为 2025 年 8 月 27 日。 《上海证券报》和上海证券交易所网站（www.sse.com.cn）为公司信息披露 媒体，公司所有信息均以在上述媒体刊登的信息为准。敬请广大投资者关注公告。 特此公告。 江苏联环药业股份有限公司董事会 2025 年 8 月 26 日 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Group 1 - The stock of Lianhuan Pharmaceutical (600513) experienced a limit down today, with a turnover rate of 21.27% and a trading volume of 1.644 billion yuan, showing a fluctuation of 11.46% [1] - The stock was listed on the Shanghai Stock Exchange due to a daily decline deviation of -10.13%, with a net selling amount of 44.7459 million yuan from brokerage seats [2] - In the past six months, the stock has appeared on the龙虎榜 (Dragon and Tiger List) nine times, with an average price increase of 2.65% the day after being listed and an average increase of 8.92% over the following five days [3] Group 2 - For Q1, Lianhuan Pharmaceutical reported a revenue of 628 million yuan, representing a year-on-year growth of 18.78%, while net profit was 23.0596 million yuan, a year-on-year decline of 29.15% [4] - The company issued a half-year performance forecast on July 15, expecting a net loss between 45 million yuan and 38 million yuan, indicating a year-on-year change range of -171.56% to -160.42% [5] - The top buying brokerage on August 21 was Guotai Junan Securities, with a purchase amount of 74.1533 million yuan, while the top selling brokerage was CITIC Securities, with a selling amount of 55.9735 million yuan [5]

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

Market Overview - The A-share market experienced a sudden decline in the afternoon, with the Shanghai Composite Index dropping over 0.2% before recovering slightly, while the Shenzhen Component and ChiNext indices fell [2] - The trading volume in the Shanghai and Shenzhen markets exceeded 2 trillion yuan for the first time this year, marking the seventh consecutive trading day of such volume [2] Sector Performance - Securities stocks collectively faced a pullback, with notable declines including Changcheng Securities down over 6% and Hato Securities down over 5% [2][3] - Several high-priced stocks hit the daily limit down, including Lianhuan Pharmaceutical and Zhongdian Xindong, with others like Shunlian Bio and Sainuo Medical dropping over 8% [4] Banking Sector - In contrast, bank stocks showed strength in the afternoon, with Agricultural Bank of China and Postal Savings Bank reaching new historical highs during the session [2] Hong Kong Market - The Hang Seng Index fell over 0.5%, and the Hang Seng Tech Index dropped more than 1% [6] - AAC Technologies Holdings (02018.HK) saw a rapid decline of over 14% following the release of its interim results, despite reporting a revenue of 13.32 billion yuan, a year-on-year increase of 18.4% [6][8] Company Performance - AAC Technologies reported a gross margin of 20.7%, down 0.8 percentage points year-on-year, attributed to changes in product mix, while net profit attributable to shareholders increased by 63.1% to 876 million yuan due to improved profitability in optical business and rapid growth in precision structural components [8] - CICC noted that the overall valuation level of A-shares remains reasonable, but the rapid increase in trading volume may lead to short-term volatility [8]

Group 1 - The stock of Lianhuan Pharmaceutical experienced a significant drop, closing at 25.91 yuan, down 2.88 yuan or 10.00% from the previous trading day, with over 28,521 sell orders waiting, indicating nearly 74 million yuan in funds attempting to exit [1] - Lianhuan Pharmaceutical's stock had previously surged by 240.67% from June 24 to August 20, reaching a peak price of 31.58 yuan, highlighting the adjustment pressure following such a substantial increase [2][4] - The market speculation around Lianhuan Pharmaceutical is primarily driven by its innovative drug project LH-1801, which targets a large market for diabetes treatment, directly competing with AstraZeneca's Dapagliflozin, projected to generate 7.7 billion USD in global sales by 2024 [4] Group 2 - The company announced a projected loss of 38 to 45 million yuan for the first half of 2025, a shift from profit to loss, mainly due to monopoly fines and losses from subsidiaries [4] - Lianhuan Pharmaceutical faced a fine of 61.04 million yuan for monopolistic practices related to the price of Dexamethasone phosphate raw materials, which accounts for 72.53% of the projected net profit for 2024 [4] - The company's main business segments include tablets, medical devices, raw materials, and injections, contributing 49.32%, 24.8%, 12.95%, and 4.02% to total revenue, respectively [4]

Group 1 - A-share market experienced a decline in high-performing stocks in the afternoon session, with several companies hitting the daily limit down [1] - Notable companies that faced significant drops include Lianhuan Pharmaceutical, Zhongdian Xindong, Feilong Co., Jintian Co., which all hit the limit down, while Shenlian Biological, Sainuo Medical, Jimin Health, Wolong Electric Drive, Chuanrun Co., Hanzhong Precision, and Guangsheng Tang all fell over 8% [1]

Group 1 - A-share market experienced a decline in high-performing stocks in the afternoon session, with companies such as Lianhuan Pharmaceutical, Zhongdian Xilong, Feilong Co., and Jintian Co. hitting the daily limit down [1] - Other companies like Shenlian Bio, Sainuo Medical, Jimin Health, Wolong Electric Drive, Chuanrun Co., Hanzhong Precision, and Guangsheng Tang saw declines exceeding 8% [1] Group 2 - MACD golden cross signal has formed, indicating a positive trend for certain stocks [2]

证券时报·数据宝统计显示，联环药业所属的医药生物行业，目前整体跌幅为0.49%，行业内，目前股价 上涨的有110只，涨停的有天目药业、易明医药等4只。股价下跌的有370只，跌幅居前的有贝达药业、 山外山、博迅生物等，跌幅分别为10.07%、8.12%、8.02%。 公司发布的一季报数据显示，一季度公司共实现营业收入6.28亿元，同比增长18.78%，实现净利润 2305.96万元，同比下降29.15%，基本每股收益为0.0800元，加权平均净资产收益率1.64%。 7月15日公司发布上半年业绩预告，预计实现净利润-4500.00万元至-3800.00万元，同比变动区间 为-171.56%~-160.42%。（数据宝） 联环药业股价再创历史新高，该股近期呈不断突破新高之势，近一个月累计有11个交易日股价刷新历史 纪录。截至09:38，该股目前上涨4.14%，股价报30.69元，成交1088.78万股，成交金额3.26亿元，换手 率3.81%，该股最新A股总市值达87.61亿元，该股A股流通市值87.61亿元。 （文章来源：证券时报网） ...

Group 1 - Tenglong Co., Ltd. has small batch products indirectly applied in data center/server liquid cooling and energy storage liquid cooling fields [1] - Fuyao Glass reported a 37.33% year-on-year increase in net profit for the first half of 2025, reaching 4.805 billion yuan [2] - Huihong Group plans to dispose of certain financial assets, including stocks of Hongye Futures, Zhongtai Securities, and Shengyi Technology, to optimize asset structure [3] Group 2 - Zhongheng Electric clarified that it has not signed cooperation agreements with overseas cloud companies like NVIDIA, Meta, and Google [4] - Kosen Technology announced it does not produce robot products, despite recent stock price fluctuations [5] - Garden Shares stated it does not have a controlling relationship with Yunzhin Technology [6] Group 3 - Yiling Pharmaceutical's new drug application for "Children's Lianhua Qinggan Granules" has been accepted by the National Medical Products Administration [7] - Zhuochuang Information plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [8] - Lianhuan Pharmaceutical's new oral solution production line has passed GMP compliance inspection [9] Group 4 - Xianda Co., Ltd. reported a 2561.58% year-on-year increase in net profit for the first half of 2025, reaching 136 million yuan [10] - Jiangte Motor announced that its subsidiary Yichun Silver Lithium will resume production soon [11] - Dameng Data's board member and general manager is under investigation [12] Group 5 - Dongjie Intelligent is planning a change in control, leading to a suspension of its stock and convertible bonds [13] - Gibit reported a 24.50% year-on-year increase in net profit for the first half of 2025, amounting to 645 million yuan [14] - Wuzhou Special Paper's net profit decreased by 47.57% year-on-year to 122 million yuan [15] Group 6 - Harbin Air Conditioning reported a loss of 7.64 million yuan for the first half of 2025, reversing from profit [16] - Tibet Tourism achieved a net profit of 2.09 million yuan, turning around from a loss of 2.58 million yuan in the previous year [17]

证券日报网讯 8月19日晚间，联环药业发布公告称，近日，公司全资子公司联环药业（安庆）有限公司 从安徽省药品监督管理局网站获悉《药品GMP符合性检查告知书》（皖药〔2025〕146号）。 （编辑 楚丽君） ...